Really enjoyed speaking today about our work on the dos and don’ts of de novo protein design for immunotherapy w/ @hoyin_chu. Grateful for the invitation to this awesome seminar series.
⚠️ If you’re reading this, you’ve been infected* ⚠️
*~95% the human population has been infected by the Epstein-Barr Virus (EBV).
Today in @Nature with @nyeo_sherry, @EMC22381830, @RyanDhindsa@SlavePetrovski, we shed some light on what happens next.
https://t.co/Db1j4aHeFO
@CalebLareau@hoyin_chu My first deep dive into computational protein design and I’m officially hooked.
We show that while zero shot de novo binder design at scale is feasible, translating these molecules into therapeutic grade candidates requires substantial work under the hood.
Feedback welcome!
Extremely proud of the work our team put together and grateful to everyone who made this possible as it heads out into the world. Huge thanks to @CalebLareau and @hoyin_chu for tackling this fun scientific adventure with me.
Excited to share the first preprint of a new direction for our group. Led by the fearless duo of @arthurwchow and @hoyin_chu, our foray into computational protein design— 1/n
https://t.co/o5kDJ5TiWr
Building CAR-T 🏎️ cells from scratch - not borrowed parts. In @CalebLareau’s lab, @arthurwchow is designing custom binders from scratch + stress-testing them in record time - engineering CAR-Ts built to win the race against cancer 🏁